← Back to Search

Botulinum Toxin Type A for Esophageal Cancer

Phase 2
Waitlist Available
Led By Moshim Kukar
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 90
Awards & highlights

Study Summary

This study is evaluating whether botulinum toxin type A can prevent complications after surgery in patients with esophageal cancer.

Eligible Conditions
  • Esophageal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 90
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study
Secondary outcome measures
Delayed Gastric Emptying Assessed Radiographically by Gastrografin Swallow OR CT Esophagram
Gastrointestinal and Nutritional Status Including Days to Resumption of Oral Feeding as Assessed by Dietician
Hospital Length of Stay Attributed to Delayed Gastric Emptying
+3 more

Side effects data

From 2010 Phase 4 trial • 50 Patients • NCT01004042
4%
Edema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Non Depressed Subjects
Depressed Subjects

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (botulinum toxin type A, esophagectomy)Experimental Treatment3 Interventions
Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
Group II: Arm II (esophagectomy)Active Control2 Interventions
Patients undergo standard minimally invasive esophagectomy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Botulinum toxin type A
FDA approved
Esophagectomy
2016
Completed Phase 3
~4130

Find a Location

Who is running the clinical trial?

Roswell Park Cancer InstituteLead Sponsor
402 Previous Clinical Trials
30,774 Total Patients Enrolled
Moshim KukarPrincipal InvestigatorRoswell Park Cancer Institute
1 Previous Clinical Trials
6 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
2016. "Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02965976.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top